{"id":"W4410708315","doi":"10.1016/j.jtho.2025.05.016","title":"Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eisai Incorporated; Merck Sharp and Dohme; Eisai Canada; Eisai; Merck; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Pembrolizumab; Oncology; Lenvatinib; Lung cancer; Internal medicine; Atezolizumab; Nivolumab; Cancer; Chemotherapy; Immunotherapy; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002652561,0.001253541,0.001742036,0.0002876123,0.0004733478,0.001220117,0.001311159,0.001468887,0.007639347],"category_scores_gemma":[0.001058389,0.0005037097,0.002102209,0.000422283,0.0006096532,0.0008617603,0.0005335486,0.003571269,0.001616405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001148799,"about_ca_system_score_gemma":0.002488704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001223863,"about_ca_topic_score_gemma":0.003591517,"domain_scores_codex":[0.9993667,0.0003516415,0.00002980484,0.00008500494,0.0000864192,0.00008050317],"domain_scores_gemma":[0.9992535,0.0001004434,0.0001484165,0.00006250651,0.00006230486,0.0003728955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8545895,0.03882241,0.005668552,0.00174302,0.003711489,0.0002803138,0.0001523252,0.001552241,0.01523505,0.0003047592,0.01031881,0.06762166],"study_design_scores_gemma":[0.8763552,0.1061604,0.009452024,0.00007735385,0.0009773171,0.0003054106,0.00002852177,0.0006802476,0.001377548,0.0002164738,0.004341136,0.00002835476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9622779,0.009249371,0.001350927,0.001849507,0.0003391351,0.009426178,0.008647432,0.0002995553,0.006560024],"genre_scores_gemma":[0.9532681,0.005891408,0.003854486,0.003618877,0.0003693205,0.01252734,0.01304545,0.00007369502,0.007351381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007639347,"threshold_uncertainty_score":0.02555615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04779553451295115,"score_gpt":0.4649378753724637,"score_spread":0.4171423408595126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}